MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable
pipeline of "matured" and "innovative drugs" in today's global healthcare market.
The product name change from Lomustine (CCNU) to GleostineTM represents the company's strategic initiative to re-launch and re-brand its product pipeline of matured and
MIAMI, Jan. 24, 2014 -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company
focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU)...
MIAMI, Sept. 23, 2013 -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with
a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets.
By utilizing a worldwide distribution network...
Counterfeit medicine is fake medicine. It may be contaminated or contain the wrong or no active ingredient.
They could have the right active ingredient but at the wrong dose. Counterfeit drugs are illegal and may
be harmful to your health. FDA takes all reports of suspect counterfeits seriously and, in order to combat
counterfeit medicines, is working with other agencies and the private sector to help protect the nation’s
drug supply from the threat of counterfeits.
4300 SW 73rd Avenue
Terms & Conditions
The product information provided in this site is intended only for residents of the United States.
The products discussed herein may have different product labeling in different countries.